在真实案例场景中使用基于大语言模型的人工智能对糖尿病患者进行糖尿病视网膜病变初步筛查的建议。

IF 1.9 Q2 OPHTHALMOLOGY
Nikhil Gopalakrishnan, Aishwarya Joshi, Jay Chhablani, Naresh Kumar Yadav, Nikitha Gurram Reddy, Padmaja Kumari Rani, Ram Snehith Pulipaka, Rohit Shetty, Shivani Sinha, Vishma Prabhu, Ramesh Venkatesh
{"title":"在真实案例场景中使用基于大语言模型的人工智能对糖尿病患者进行糖尿病视网膜病变初步筛查的建议。","authors":"Nikhil Gopalakrishnan, Aishwarya Joshi, Jay Chhablani, Naresh Kumar Yadav, Nikitha Gurram Reddy, Padmaja Kumari Rani, Ram Snehith Pulipaka, Rohit Shetty, Shivani Sinha, Vishma Prabhu, Ramesh Venkatesh","doi":"10.1186/s40942-024-00533-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To study the role of artificial intelligence (AI) to identify key risk factors for diabetic retinopathy (DR) screening and develop recommendations based on clinician and large language model (LLM) based AI platform opinions for newly detected diabetes mellitus (DM) cases.</p><p><strong>Methods: </strong>Five clinicians and three AI applications were given 20 AI-generated hypothetical case scenarios to assess DR screening timing. We calculated inter-rater agreements between clinicians, AI-platforms, and the \"majority clinician response\" (defined as the maximum number of identical responses provided by the clinicians) and \"majority AI-platform\" (defined as the maximum number of identical responses among the 3 distinct AI). Scoring was used to identify risk factors of different severity. Three, two, and one points were given to risk factors requiring screening immediately, within a year, and within five years, respectively. After calculating a cumulative screening score, categories were assigned.</p><p><strong>Results: </strong>Clinicians, AI platforms, and the \"majority clinician response\" and \"majority AI response\" had fair inter-rater reliability (k value: 0.21-0.40). Uncontrolled DM and systemic co-morbidities required immediate screening, while family history of DM and a co-existing pregnancy required screening within a year. The absence of these risk factors required screening within 5 years of DM diagnosis. Screening scores in this study were between 0 and 10. Cases with screening scores of 0-2 needed screening within 5 years, 3-5 within 1 year, and 6-12 immediately.</p><p><strong>Conclusion: </strong>Based on the findings of this study, AI could play a critical role in DR screening of newly diagnosed DM patients by developing a novel DR screening score. Future studies would be required to validate the DR screening score before it could be used as a reference in real-life clinical situations.</p><p><strong>Clinical trial registration: </strong>Not applicable.</p>","PeriodicalId":14289,"journal":{"name":"International Journal of Retina and Vitreous","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809735/pdf/","citationCount":"0","resultStr":"{\"title\":\"Recommendations for initial diabetic retinopathy screening of diabetic patients using large language model-based artificial intelligence in real-life case scenarios.\",\"authors\":\"Nikhil Gopalakrishnan, Aishwarya Joshi, Jay Chhablani, Naresh Kumar Yadav, Nikitha Gurram Reddy, Padmaja Kumari Rani, Ram Snehith Pulipaka, Rohit Shetty, Shivani Sinha, Vishma Prabhu, Ramesh Venkatesh\",\"doi\":\"10.1186/s40942-024-00533-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To study the role of artificial intelligence (AI) to identify key risk factors for diabetic retinopathy (DR) screening and develop recommendations based on clinician and large language model (LLM) based AI platform opinions for newly detected diabetes mellitus (DM) cases.</p><p><strong>Methods: </strong>Five clinicians and three AI applications were given 20 AI-generated hypothetical case scenarios to assess DR screening timing. We calculated inter-rater agreements between clinicians, AI-platforms, and the \\\"majority clinician response\\\" (defined as the maximum number of identical responses provided by the clinicians) and \\\"majority AI-platform\\\" (defined as the maximum number of identical responses among the 3 distinct AI). Scoring was used to identify risk factors of different severity. Three, two, and one points were given to risk factors requiring screening immediately, within a year, and within five years, respectively. After calculating a cumulative screening score, categories were assigned.</p><p><strong>Results: </strong>Clinicians, AI platforms, and the \\\"majority clinician response\\\" and \\\"majority AI response\\\" had fair inter-rater reliability (k value: 0.21-0.40). Uncontrolled DM and systemic co-morbidities required immediate screening, while family history of DM and a co-existing pregnancy required screening within a year. The absence of these risk factors required screening within 5 years of DM diagnosis. Screening scores in this study were between 0 and 10. Cases with screening scores of 0-2 needed screening within 5 years, 3-5 within 1 year, and 6-12 immediately.</p><p><strong>Conclusion: </strong>Based on the findings of this study, AI could play a critical role in DR screening of newly diagnosed DM patients by developing a novel DR screening score. Future studies would be required to validate the DR screening score before it could be used as a reference in real-life clinical situations.</p><p><strong>Clinical trial registration: </strong>Not applicable.</p>\",\"PeriodicalId\":14289,\"journal\":{\"name\":\"International Journal of Retina and Vitreous\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809735/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Retina and Vitreous\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s40942-024-00533-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Retina and Vitreous","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40942-024-00533-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:研究人工智能(AI)在确定糖尿病视网膜病变(DR)筛查的关键风险因素方面的作用,并根据临床医生和基于大型语言模型(LLM)的人工智能平台对新发现的糖尿病(DM)病例的意见提出建议:五位临床医生和三款人工智能应用软件在人工智能生成的 20 个假设病例场景中评估 DR 筛查时机。我们计算了临床医生、人工智能平台以及 "多数临床医生回复"(定义为临床医生提供的相同回复的最大数量)和 "多数人工智能平台"(定义为 3 个不同人工智能中相同回复的最大数量)之间的互评一致率。评分用于识别不同严重程度的风险因素。对需要立即筛查、一年内筛查和五年内筛查的风险因素分别给予 3 分、2 分和 1 分。在计算累计筛查得分后,进行分类:结果:临床医生、人工智能平台、"多数临床医生响应 "和 "多数人工智能响应 "的评分者之间的可靠性尚可(k 值:0.21-0.40)。未控制的糖尿病和系统性合并疾病需要立即进行筛查,而糖尿病家族史和合并妊娠需要在一年内进行筛查。如果没有这些危险因素,则需要在确诊糖尿病后 5 年内进行筛查。本研究中的筛查评分在 0-10 分之间。筛查评分为 0-2 分的病例需要在 5 年内进行筛查,3-5 分的病例需要在 1 年内进行筛查,6-12 分的病例需要立即进行筛查:根据这项研究的结果,人工智能可以通过制定新的 DR 筛查评分,在新诊断的 DM 患者的 DR 筛查中发挥关键作用。临床试验注册:临床试验注册:不适用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Recommendations for initial diabetic retinopathy screening of diabetic patients using large language model-based artificial intelligence in real-life case scenarios.

Purpose: To study the role of artificial intelligence (AI) to identify key risk factors for diabetic retinopathy (DR) screening and develop recommendations based on clinician and large language model (LLM) based AI platform opinions for newly detected diabetes mellitus (DM) cases.

Methods: Five clinicians and three AI applications were given 20 AI-generated hypothetical case scenarios to assess DR screening timing. We calculated inter-rater agreements between clinicians, AI-platforms, and the "majority clinician response" (defined as the maximum number of identical responses provided by the clinicians) and "majority AI-platform" (defined as the maximum number of identical responses among the 3 distinct AI). Scoring was used to identify risk factors of different severity. Three, two, and one points were given to risk factors requiring screening immediately, within a year, and within five years, respectively. After calculating a cumulative screening score, categories were assigned.

Results: Clinicians, AI platforms, and the "majority clinician response" and "majority AI response" had fair inter-rater reliability (k value: 0.21-0.40). Uncontrolled DM and systemic co-morbidities required immediate screening, while family history of DM and a co-existing pregnancy required screening within a year. The absence of these risk factors required screening within 5 years of DM diagnosis. Screening scores in this study were between 0 and 10. Cases with screening scores of 0-2 needed screening within 5 years, 3-5 within 1 year, and 6-12 immediately.

Conclusion: Based on the findings of this study, AI could play a critical role in DR screening of newly diagnosed DM patients by developing a novel DR screening score. Future studies would be required to validate the DR screening score before it could be used as a reference in real-life clinical situations.

Clinical trial registration: Not applicable.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.50
自引率
4.30%
发文量
81
审稿时长
19 weeks
期刊介绍: International Journal of Retina and Vitreous focuses on the ophthalmic subspecialty of vitreoretinal disorders. The journal presents original articles on new approaches to diagnosis, outcomes of clinical trials, innovations in pharmacological therapy and surgical techniques, as well as basic science advances that impact clinical practice. Topical areas include, but are not limited to: -Imaging of the retina, choroid and vitreous -Innovations in optical coherence tomography (OCT) -Small-gauge vitrectomy, retinal detachment, chromovitrectomy -Electroretinography (ERG), microperimetry, other functional tests -Intraocular tumors -Retinal pharmacotherapy & drug delivery -Diabetic retinopathy & other vascular diseases -Age-related macular degeneration (AMD) & other macular entities
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信